



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Hasson et al.

SERIAL NUMBER : 10/564,760

EXAMINER : Lora Elizabeth Barnhart

FILING DATE : July 7, 2006

ART UNIT : 1651

FOR : EX VIVO PROGENITOR AND STEM CELL EXPANSION FOR USE IN
THE TREATMENT OF DISEASE OF ENDODERMALLY-DERIVED
ORGANS

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (5 pages), in duplicate;
3. Copies of Cited References: B1-B15; C1-C49; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24024-513 NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Ivor R. Elrifi".

Ivor R. Elrifi, Reg. No. 39,529

Matthew Pavao, Reg. No. 50,572

Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer No.: 30623

Tel: (617) 542-6000

Date: May 10, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Hasson et al.

SERIAL NUMBER : 10/564,760

EXAMINER : Lora Elizabeth Barnhart

FILING DATE : July 7, 2006

ART UNIT : 1651

FOR : EX VIVO PROGENITOR AND STEM CELL EXPANSION FOR USE IN
THE TREATMENT OF DISEASE OF ENDODERMALLY-DERIVED
ORGANS

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before receipt of a first Office Action on the merits. Accordingly, no fee is believed due. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A37 and U.S. Published Applications A38-A45 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.



APPLICANTS: **Hasson et al.**
U.S.S.N.: **10/564,760**

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24024-513 NATL.



Ivor R. Elrifi, Reg. No. 39,529

Matthew Pavao, Reg. No. 50,572

Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer No.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: May 10, 2007

4039270v.1

Express Mail No.: EV 923351720 US
Date of Deposit: May 10, 2007



Page 1 of 5
Attorney Docket No.: 24024-513 NATL

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO				Application Number		10/564,760	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date		July 7, 2006	
				First Named Inventor		Hasson	
				Group Art Unit		1651	
				Examiner Name		Lora Elizabeth Barnhart	
				Attorney Docket Number		24024-513 NATL	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	3,715,345	06-06-1973	Smith			
	*A2	3,863,008	01-28-1975	Grant			
	*A3	3,876,623	08-08-1975	Jackson et al.			
	*A4	4,476,301	09-09-1984	Imbach et al.			
	*A5	4,806,484	02-21-1989	Petrossian et al.			
	*A6	4,816,567	03-28-1989	Cabilly et al.			
	*A7	4,946,778	07-07-1990	Ladner et al.			
	*A8	5,081,035	01-14-1992	Halberstadt et al.			
	*A9	5,264,562	11-23-1993	Matteucci			
	*A10	5,264,564	11-23-1993	Matteucci			
	*A11	5,320,963	06-14-1994	Knaack et al.			
	*A12	5,342,781	08-30-1994	Su			
	*A13	5,378,725	03-03-1995	Bonjouklian et al.			
	*A14	5,466,677	11-14-1995	Baxter et al.			
	*A15	5,476,925	12-19-1995	Letsinger et al.			
	*A16	5,519,126	05-21-1996	Hecht			
	*A17	5,536,821	07-16-1996	Agrawal et al.			
	*A18	5,539,082	07-23-1996	Nielsen et al.			
	*A19	5,541,306	07-30-1996	Agrawal et al.			
	*A20	5,545,806	08-13-1996	Lonberg et al.			
	*A21	5,545,807	08-13-1996	Surani et al.			
	*A22	5,550,111	08-27-1996	Suhadolnik et al.			
	*A23	5,569,825	10-29-1996	Lonberg et al.			

	*A24	5,612,211	03-18-1997	Wilson et al.			
	*A25	5,623,070	04-22-1997	Cook et al.			
	*A26	5,625,126	04-29-1997	Lonberg et al.			
	*A27	5,633,425	05-27-1997	Lonberg et al.			
	*A28	5,661,016	08-26-1997	Lonberg et al.			
	*A29	5,674,750	07-07-1997	Kraus et al.			
	*A30	5,712,154	01-27-1998	Mullon et al.			
	*A31	5,714,331	03-03-1998	Buchardt et al.			
	*A32	5,719,262	02-17-1998	Buchardt et al.			
	*A33	6,303,374	10-16-2001	Zhang et al.			
	*A34	6,326,174	04-04-2001	Joyce et al.			
	*A35	6,338,942	01-15-2002	Kraus et al.			
	*A36	6,642,019	04-04-2003	Anderson et al.			
	*A37	6,680,166	01-20-2004	Mullon et al.			

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A38	2001/0014475	08-16-2001	Frondoza et al.			
	*A39	2002/0146678	10-10-2002	Benvenisty			
	*A40	2002/0146816	10-10-2002	Vellinger et al.			
	*A41	2003/0002363	02-02-2003	Le et al.			
	*A42	2003/0125410	03-03-2003	Keita et al.			
	*A43	2003/0149074	07-07-2003	Melese et al.			
	*A44	2003/0235909	12-25-2003	Hariri et al.			
	*A45	2006/0205071	09-14-2006	Hasson et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO	95/14078	Cameron, Robert	05-26-1995		
	B2	WO	95/21911	Goffe, Randal	08-17-1995		
	B3	WO	95/24464	Sandstrom et al.	09-14-1995		
	B4	WO	96/01108	Creemer et al.	01-18-1996		
	B5	WO	96/40876	Tucker et al.	12-19-1996		
	B6	WO	97/04707	Aoyama et al.	02-13-1997	Abstract only	
	B7	WO	00/46349	Merchav et al.	08-10-2000		

FOREIGN PATENT DOCUMENTS								
Exam Initials		Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
		B8	WO	00/66712	Oles et al.	11-09-2000		
		B9	WO	00/73421 A2	Hu et al.	12-07-2000		
		B10	WO	02/064755 A2	Hariri, Robert	08-22-2002		
		B11	WO	02/080995 A1	Nevo et al.	10-17-2002		
		B12	WO	03/004626 A2	Zandstra et al.	01-16-2003		
		B13	WO	03/072557 A1	Bruce et al.	09-04-2003		
		B14	WO	2005/007073 A2	Marikovsky et al.	01-27-2005		
		B15	WO	2005/007799 A2	Hasson et al.	01-27-2005		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Aoki et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides Into the Myocardium Using HVJ-Liposome Method", Biochemical and Biophysical Research Communications, 231: 540-545, 1997.
	C2	Auger et al. "PDGF-Dependent Tyrosine Phosphorylation Stimulates Production of Novel Polyphosphoinositides in Intact Cells", Cell, 57: 167-175, 1989.
	C3	Bird et al. "Single-Chain Antigen-Binding Proteins", Science, 242: 423-426, 1988.
	C4	Boerner et al. "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes", The Journal of Immunology, 147(1): 86-95, 1991.
	C5	Brott et al. "Flow Cytometric Characterization of Perfused Human Bone Marrow Cultures: Identification of the Major Cell Lineages and Correlation With the CFU-GM Assay", Cytometry Part A, 53A: 22-27, 2003.
	C6	Butt "Introduction to Chemical Reactor Theory", Reaction Kinetics and Reactor Design, Chap.4: 184-241, 1980.
	C7	Cole et al. "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer", Monoclonal Antibodies and Cancer Therapy, P.77-96, 1985.
	C8	Collins et al. "Stirred Culture of Peripheral and Cord Blood Hematopoietic Cells Offers Advantages Over Traditional Static Systems for Clinically Relevant Applications", Biotechnology and Bioengineering, 59(5): 534-543, 1998.
	C9	Czyz et al. "Potential of Embryonic and Adult Stem Cell In Vitro", Biological Chemistry, 384: 1391-1409, 2003.
	C10	Ehring et al. "Expansion of HPCs From Cord Blood in A Novel 3D Matrix", Cytotherapy, 5(6): 490-499, 2003.
	C11	Fishwild et al. "High-Avidity Human IgGκ Monoclonal Antibodies From A Novel Strain of Minilocus Transgenic Mice", Nature Biotechnology, 14: 845-851, 1996.
	C12	Gloeckner et al. "New Miniaturized Hollow-Fiber Bioreactor for In Vivo Like Cell Culture, Cell Expansion, and Production of Cell-Derived Products", Biotechnology Progresses, 17: 828-831, 2001.
	C13	Hoogenboom et al. " Human Antibodies From Synthetic Repertoires of Germline VH Gene Segments Rearranged In Vitro", Journal of Molecular Biology, 227: 381-388, 1992.
	C14	Hori et al. "Growth Inhibitors Promote Differentiation of Insulin-Producing Tissue From Embryonic Stem Cells", Proc. Natl. Acad. Sci. USA, 99(25): 16105-16110, 2002.
	C15	Hutvagner et al. "RNAi: Nature Abhors A Double-Strand", Current Opinion in Genetics & Development, 12: 225-232, 2002.
	C16	Inbar et al. "Localization of Antibody-Combining Sites Within the Variable Portions of Heavy and Light Chains", Proc. Natl. Acad. Sci. USA, 69(9): 2659-2662, 1972.
	C17	Jelinek et al. "Novel Bioreactors for the Ex Vivo Cultivation of Hematopoietic Cells", English Life Science, 2(1): 15-18, 2002.
	C18	Jones et al. "Replacing the Complementarity-Determining Regions in A Human Antibody With Those From A Mouse", Nature, 321: 522-525, 1986.
	C19	Kawa et al. "Stem Cell Factor and/or Endothelin-3 Dependent Immortal Melanoblast and Melanocyte Populations

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		Derived From Mouse Neural Crest Cells", Pigment Cell Research, 13(Suppl.8): 73-80, 2000.
	C20	Khachigian "DNAzymes: Cutting A Path to A New Class of Therapeutics", Current Opinion in Molecular Therapeutics, 4(2): 119-121, 2002.
	C21	Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset", Blood, 91(3): 852-862, 1998.
	C22	Lavigne et al. "Enhanced Antisense Inhibition of Human Immunodeficiency Virus Type 1 in Cell Cultures by DLS Delivery System", Biochemical and Biophysical Research Communications, 237: 566-571, 1997.
	C23	Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications", Nature, 368: 856-859, 1994.
	C24	Lonberg et al. "Human Antibodies From Transgenic Mice", International Review in Immunology, 13: 65-93, 1995.
	C25	Luft " Making Sense Out of Antisense Oligodeoxynucleotide Delivery: Getting There Is Half the Fun". J. Mol. Med, P.75-76. 1998.
	C26	Marks et al. "By-Passing Immunization - Human Antibodies From V-Gene Libraries Displayed on Phage", Journal of Molecular Biology, 222: 581-597, 1991.
	C27	Marks et al. "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", Bio/Technology, 10: 779-783, 1992.
	C28	Matuoka et al. " A Positive Role of Phosphatidylinositol 3-Kinase in Aging Phenotype Expression in Cultured Human Diploid Fibroblasts", Arch. Gerontol. Geriatrics, 36:203-219, 2003.
	C29	Meissner et al. "Development of A Fixed Bed Bioreactor for the Expansion of Human Hematopoietic Progenitor Cells", Cytotechnology, 30: 227-234, 1999.
	C30	Moore "Putting the Neo Into Neoangiogenesis", The Journal of Clinical Investigation, 109(3): 313-315, 2002.
	C31	Morrison "Success in Specification", Nature, 368(6474): 812-813, 1994.
	C32	Munshi et al. "Evidence For a Casual Role Of CD38 Expression In Granulocytic Differentiation of Human HL-60 Cells", The Journal of Biological Chemistry, 277(51): 49453-49458, 2002.
	C33	Neuberger "Generating High-Avidity Human Mabs in Mice", Nature Biotechnology, 14: 826, 1996.
	C34	Ohishi et al. "Delta-1 Enhances Marrow and Thymus Repopulating Ability of Human CD34+CD38- Cord Blood Cells", The Journal of Clinical Investigation, 110(8): 1165-1174, 2002.
	C35	Pei et al. "Bioreactors Mediate the Effectiveness of Tissue Engineering Scaffolds", The FASEB Journal, 16: 1691-1694, 2002.
	C36	Petzer et al. "Differential Cytokine Effects on Primitive (CD34+CD38-) Human Hematopoietic Cells: Novel Responses to Flt3-Ligand and Thrombopoietin", Journal of Experimental Medicine, 183: 2551-2558, 1996.
	C37	Porter "The Hydrolysis of Rabbit ?-Globulin and Antibodies With Crystalline Papain", Biochemical Journal, 73: 119-126, 1959.
	C38	Porter et al. "Graft-Versus-Leukemia Effect of Allogeneic Bone Marrow Transplantation and Donor Mononuclear Cell Infusions", Cancer Treatment & Research, 77: 57-85, 1997. Abstract.
	C39	Presta "Antibody Engineering", Current Opinion in Structural Biology, 2: 593-596, 1992.
	C40	Punzel et al. "The Type of Stromal Feeder Used in Limiting Dilution Assays Influences Frequency and Maintenance Assessment of human Long-Term Culture Initiating Cells", Leukemia, 13: 92-97, 1999.
	C41	Rajur et al. "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules", Bioconjugate Chemistry, 8(6): 935-940, 1997.
	C42	Reyes et al. "Origin of Endothelial Progenitors in Human Postnatal Bone Marrow", Journal of Clinical Investigation, 109: 337-346, 2002.
	C43	Riechmann et al. "Reshaping Human Antibodies for Therapy", Nature, 332: 323-327, 1988.
	C44	Ryu et al. "Adenosine Triphosphate Induces Proliferation of Human Neural Stem Cells: Role of Calcium and P70 Ribosomal Protein S6 Kinase", Journal of Neuroscience Research, 72: 352-362, 2003.
	C45	Santoro et al. "A General Purpose RNA-Cleaving DNA Enzyme", Proc. Natl. Acad. Sci. USA, 94: 4262-4266, 1997.
	C46	Verhoeven et al. "Reshaping Human Antibodies: Grafting An Antilysozyme Activity", Science, 239: 1534-1536, 1988.

Express Mail No.: EV 923351720 US
Date of Deposit: May 10, 2007

Page 5 of 5
Attorney Docket No.: 24024-513 NATL

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C47	Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to A Structured RNA Target", Biotechnology and Bioengineering, 65(1): 1-9, 1999.
	C48	Whitlow et al. "Single-Chain Fv Proteins and Their Fusion Proteins", Methods: A Companion to Methods in Enzymology, 2(2): 97-105, 1991.
	C49	Zenith "Zenith and US Robotics, A Complete Network Solution for Data Modem Communications Over One-Way Cable Plants", Zenith Network Systems Data Business Unit.

*** By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A37 and U.S. Published Applications A38-A45 are not submitted.**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4038252v.1